Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

Trans Texans are concerned about the threats that SB 240 could create for their safety, physical health and ability to ...

Concorde International Group Ltd. (NASDAQ: CIGL) ("Concorde" or the "Company"), an integrated security services provider that combines physical manpower ...

The Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Class A Ordinary Shares at the public offering price, less underwriting discounts.